The usual adult dosage is 1 or 2 mg 2 times a day. On the day of chemotherapy, the initial dose should be given 1 to 3 hours before the chemotherapeutic agent is administered. To minimize side effects, it is recommended that the lower starting dose be used and that the dose be increased as necessary. A dose of 1 or 2 mg the night before may be useful. The maximum recommended daily dose is 6 mg given in divided doses 3 times a day.
Cesamet may be administered 2 or 3 times a day during the entire course of each cycle of chemotherapy and, if needed, for 48 hours after the last dose of each cycle of chemotherapy.
Cesamet® capsules (blue and white): 1 mg (bottles of 50 capsules) NDC 0037-1221-50. Capsules are imprinted with MEDA on the blue cap and a four-digit code (1221) on the white body. Store at controlled room temperature, 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].
To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-723-1400 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
IN-012250-01 Rev 9/2013 Part No. 22101757
Manufactured by: Valeant Canada LP, Quebec, Canada for:
Somerset, New Jersey 08873-4120
MEDA PHARMACEUTICALS is a registered trademark of Meda AB.
©2013 Meda Pharmaceuticals Inc.
Made in Canada
CESAMET is a registered trademark of Valeant Pharmaceuticals North America LLC.
Package Label — Principal Display Panel – 50-Count Bottle Label
Each capsule contains 1 mg nabilone
|CESAMET nabilone capsule|
|Labeler — Meda Pharmaceuticals Inc. (051229602)|
Revised: 05/2015 Meda Pharmaceuticals Inc.
DrugInserts.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the US Food and Drug Administration. Package information is not reviewed or updated separately by DrugInserts.com. Every individual package label entry contains a unique identifier which can be used to secure further details directly from the US National Institutes of Health and/or the FDA.